BioXcel Therapeutics
BTAI
BTAI
93 hedge funds and large institutions have $283M invested in BioXcel Therapeutics in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
27% less capital invested
Capital invested by funds: $388M → $283M (-$105M)
38% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 24
Holders
93
Holding in Top 10
–
Calls
$4.8M
Puts
$2.88M
Top Buyers
| 1 | +$9.93M | |
| 2 | +$8.37M | |
| 3 | +$2.32M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.57M |
| 5 |
BlackRock
New York
|
+$1.48M |
Top Sellers
| 1 | -$1.8M | |
| 2 | -$1.4M | |
| 3 | -$1.25M | |
| 4 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
-$744K |
| 5 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$611K |